These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28038950)

  • 1. PCSK9 inhibitors in the current management of atherosclerosis.
    Whayne TF
    Arch Cardiol Mex; 2017; 87(1):43-48. PubMed ID: 28038950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PCSK-9 inhibitors, effects on LDL-C and future implications: What you should know].
    Corral P; Ruiz AJ
    Hipertens Riesgo Vasc; 2017; 34(4):176-183. PubMed ID: 28709786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
    Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
    Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
    Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y
    Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance.
    Koskinas K; Wilhelm M; Windecker S
    Swiss Med Wkly; 2016; 146():w14333. PubMed ID: 27400448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease.
    Alkhalil M
    Curr Drug Metab; 2019; 20(1):72-82. PubMed ID: 30112987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia.
    Whayne TF
    Am J Cardiovasc Drugs; 2016 Apr; 16(2):83-92. PubMed ID: 26596726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol and stroke: Roll of PCSK9 inhibitors.
    Castilla-Guerra L; Fernández-Moreno MC; Rico-Corral MA
    Neurologia (Engl Ed); 2019 Apr; 34(3):198-203. PubMed ID: 28549755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Sociey of Arteriosclerosis (SEA), 2019.
    Ascaso JF; Civeira F; Guijarro C; López Miranda J; Masana L; Mostaza JM; Pedro-Botet J; Pintó X; Valdivielso P
    Clin Investig Arterioscler; 2019; 31(3):128-139. PubMed ID: 31130361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding PCSK9 and anti-PCSK9 therapies.
    McKenney JM
    J Clin Lipidol; 2015; 9(2):170-86. PubMed ID: 25911073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes.
    Liberale L; Montecucco F; Camici GG; Dallegri F; Vecchie A; Carbone F; Bonaventura A
    Curr Med Chem; 2017; 24(14):1403-1416. PubMed ID: 28260498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
    Hadjiphilippou S; Ray KK
    Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.